Merck Global Health Innovation Fund

Investor type Corporate Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 68
Average round size
The average size of a deal this fund participated in
Portfolio companies 42
Rounds per year 6.18
Lead investments 7
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 21
Key employees 6

Areas of investment

  • Health Care
  • Medical
  • Information Technology
  • Biotechnology
  • Software

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Merck Global Health Innovation Fund:
Typical Co-investors
Merck Global Health Innovation Fund is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Merck Global Health Innovation Fund:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Able Partners New York, New York, United States
Arthavida Ventures -
Daun Penh Cambodia Group -
Ecosummit Berlin, Berlin, Germany
Furneaux Capital Boston, Massachusetts, United States
GKN Redditch, United Kingdom, Worcestershire
Goodwood Capital Fund Canada, Ontario, Toronto
Greater Bay Area Homeland Development Fund China, Hong Kong, Hong Kong Island
Grupo Entregas -
Houde Qianhai Fund China, Guangdong, Shenzhen
Jasper Private Equity Birmingham, England, United Kingdom
Javest Investment Fund Amsterdam, Noord-Holland, The Netherlands
Key Fund England, Sheffield, United Kingdom
Madrona Venture Labs Seattle, United States, Washington
Mayo Clinic Ventures Minnesota, Rochester, United States
Ollerhead Capital -
Service Electric Cablevision -
SINOCHEM GROUP Beijing, Beijing, China
Snapdeal Gurgaon, Haryana, India

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Octave Bioscience

Clinical Trials
Health Care
Health Diagnostics
11 Oct 2021 California, United States


Health Care
Information Technology
$58M10 Jun 2021 San Francisco, California, United States

Health Care
Health Diagnostics
$23M03 Jun 2021 London, England, United Kingdom


Health Care
Health Diagnostics
$165M18 May 2021 Boston, Massachusetts, United States


Artificial Intelligence
Life Science
Machine Learning
22 Feb 2021 Vancouver, Washington, United States


Predictive Analytics
$4M13 Nov 2020 California, United States

Koneksa Health

Big Data
Health Care
$16M28 Sep 2020 New York, New York, United States


$50M15 Sep 2020 Concord, California, United States

AeroSafe Global

$47M10 Sep 2020 Rochester, New York, United States
Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama

– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

Transcarent Raises $58 Million in Series B Funding to Accelerate Consumer-Directed Health and Care Experience for Self-Insured Employers

– Transcarent, a new and different consumer-directed health and care experience for employees of self-insured employers and their families, announced a $58m Series B investment led by General Catalyst and 7wireVentures, with participation from Merck Global Health Innovation Fund, Kleiner Perkins, Leaps by Bayer, GreatPoint Ventures, and Threshold Ventures along with existing investors Alta Partners and Jove Equity Partners.
– This round brings Transcarent’s total funding to $98m and will allow the company to respond to the demand for rapid expansion of its innovative risk-based offering for self-insured employers.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Merck Global Health Innovation Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: